Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolf Billeskov

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Human Vaccines & Immunotherapeutics|October 3, 2018
The effect of antigen dose on T cell-targeting vaccine outcomeRolf Billeskov, Babak Beikzadeh, Jay A Berzofsky
Expert Opinion on Biological Therapy|October 6, 2007
Tuberculosis subunit vaccines: from basic science to clinical testingT Mark Doherty, Jes Dietrich, Rolf Billeskov
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protectionJes Dietrich, Rolf Billeskov, T Mark Doherty, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2007
Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1Rolf Billeskov, Carina Vingsbo-Lundberg, Peter Andersen, et al.
Plos One|July 7, 2012
The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunityRolf Billeskov, Tara T Elvang, Peter L Andersen, et al.
Plos One|August 27, 2013
Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis modelRolf Billeskov, Jan P Christensen, Claus Aagaard, et al.
Plos One|June 17, 2009
Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosisTruc Thi Kim Thanh Hoang, Anneline Nansen, Sugata Roy, et al.
Frontiers in Immunology|November 26, 2020
Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb InfectionHelena Strand Clemmensen, Niels Peter Hell Knudsen, Rolf Billeskov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2017
Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective EfficacyRolf Billeskov, Yichuan Wang, Shahram Solaymani-Mohammadi, et al.
Plos One|April 10, 2009
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccinationTara Elvang, Jan P Christensen, Rolf Billeskov, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Human Vaccines & Immunotherapeutics|October 3, 2018
The effect of antigen dose on T cell-targeting vaccine outcomeRolf Billeskov, Babak Beikzadeh, Jay A Berzofsky
Expert Opinion on Biological Therapy|October 6, 2007
Tuberculosis subunit vaccines: from basic science to clinical testingT Mark Doherty, Jes Dietrich, Rolf Billeskov
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2007
Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protectionJes Dietrich, Rolf Billeskov, T Mark Doherty, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 6, 2007
Induction of CD8 T cells against a novel epitope in TB10.4: correlation with mycobacterial virulence and the presence of a functional region of difference-1Rolf Billeskov, Carina Vingsbo-Lundberg, Peter Andersen, et al.
Plos One|July 7, 2012
The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunityRolf Billeskov, Tara T Elvang, Peter L Andersen, et al.
Plos One|August 27, 2013
Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis modelRolf Billeskov, Jan P Christensen, Claus Aagaard, et al.
Plos One|June 17, 2009
Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosisTruc Thi Kim Thanh Hoang, Anneline Nansen, Sugata Roy, et al.
Frontiers in Immunology|November 26, 2020
Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb InfectionHelena Strand Clemmensen, Niels Peter Hell Knudsen, Rolf Billeskov, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 29, 2017
Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective EfficacyRolf Billeskov, Yichuan Wang, Shahram Solaymani-Mohammadi, et al.
Plos One|April 10, 2009
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccinationTara Elvang, Jan P Christensen, Rolf Billeskov, et al.
Pageof 2